---
title: "Drugs Made In America Acquisition (DMAA.US) — Financial Reports"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/DMAA.US/norm.md"
symbol: "DMAA.US"
name: "Drugs Made In America Acquisition"
parent: "https://longbridge.com/en/quote/DMAA.US.md"
datetime: "2026-03-04T02:29:45.655Z"
locales:
  - [en](https://longbridge.com/en/quote/DMAA.US/norm.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/DMAA.US/norm.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/DMAA.US/norm.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/DMAA.US/norm.md) | [繁體中文](https://longbridge.com/zh-HK/quote/DMAA.US/norm.md)


# Drugs Made In America Acquisition (DMAA.US) — Financial Reports

## Income Statement (USD)

| Indicator | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
| --- | --- | --- | --- | --- | --- |
| EPS | 0.0652 | 0.0683 | 0.0492 | -0.0327 | -0.0200 |
| ROE | -120.69% | -127.78% | -135.24% | - | 627.43% |
| Revenue | - | - | - | - | - |
| Net income | 2.18M | 2.29M | 1.25M | -279875.00 | -144928.00 |
| Operating income | -263703.00 | -131919.00 | -330925.00 | -279875.00 | -144928.00 |
| Gross margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| Profit quality | - | - | - | - | - |

## Balance Sheet (USD)

| Indicator | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
| --- | --- | --- | --- | --- | --- |
| A&L | 237.63M | 235.21M | 232.81M | 550824.00 | 426139.00 |
| Leverage | -32.43 | -32.89 | -32.44 | -2.25 | -2.58 |
| BVPS | -0.2186 | -0.2134 | -0.2141 | -0.0286 | -0.0192 |
| Turnover | - | - | - | - | - |
| Cash & STI | 717.00 | 822.00 | 923.00 | 1351.00 | 2095.00 |
| Inv & Rec | - | - | - | - | - |
| LT assets | - | - | - | - | - |
| Net debt | -717.00 | -822.00 | 59975.00 | 660973.00 | 549920.00 |

## Cash Flow Statement (USD)

| Indicator | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
| --- | --- | --- | --- | --- | --- |
| Operating CF | -56108.00 | -106655.00 | -251244.00 | -123152.00 | - |
| Investing CF | 0.0000 | 0.0000 | -231.15M | - | - |
| Financing CF | 56003.00 | 106554.00 | 231.40M | 123373.00 | - |
| Free CF | 11781.00 | -46287.00 | -120158.00 | - | - |
| OCF coverage | - | - | -27.92% | -11.97% | - |
| Repaid & issued | - | - | - | 1.39M | - |
| CapEx | - | - | - | - | - |